Literature DB >> 6811671

Similarities of murine gamma interferon and the lymphokine that renders macrophages cytotoxic.

W J Kleinschmidt, R M Schultz.   

Abstract

Murine spleen lymphoid cells treated with insoluble (Sepharose bound) concanavalin A elaborate Gamma (immune) interferon (IFN-gamma) and macrophage activation factor (MAF) into the culture medium. Similarly, MAF is produced by T cells with other IFN-gamma inducers. MAF induces resting (noncytotoxic) macrophages to become tumoricidal. We have compared various physicochemical properties of MAF and INF-gamma, their neutralization by antibody to IFN-gamma, and their induction period. In these parameters, induction of antiviral activity was compared to induction of macrophage tumoricidal activity. All of the parameters studied have given results that demonstrate close similarity in the physical properties, molecular characteristics, and biological reactivities of the two lymphokines, and this similarity suggests that these two lymphokines reside in the same molecule. This conclusion would include that IFN-gamma, like IFN-alpha and IFN-beta, is capable of activating macrophages to become cytotoxic toward tumor cells.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6811671     DOI: 10.1089/jir.1982.2.291

Source DB:  PubMed          Journal:  J Interferon Res        ISSN: 0197-8357


  14 in total

Review 1.  Macrophage diversity in cardiac inflammation: a review.

Authors:  Jobert G Barin; Noel R Rose; Daniela Ciháková
Journal:  Immunobiology       Date:  2011-06-30       Impact factor: 3.144

2.  Potentiation of direct antitumor cytotoxicity and production of tumor cytolytic factors in human blood monocytes by human recombinant interferon-gamma and muramyl dipeptide derivatives.

Authors:  S Sone; G Lopez-Berestein; I J Fidler
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

3.  Studies on macrophage-activating factor (MAF) in antitumor immune responses. II. Molecular characterization of MAF produced by the tumor-immune Lyt-1+2- T cell subset.

Authors:  H Nakajima; Y Izumi; S Sugihara; Y Satoh; S Isumi; T Gotoh; H Fujiwara; T Hamaoka
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

4.  Cellular defenses against Toxoplasma gondii in newborns.

Authors:  C B Wilson; J E Haas
Journal:  J Clin Invest       Date:  1984-06       Impact factor: 14.808

5.  T-cell hybridoma-produced lymphokine that activates macrophages to suppress intracellular growth of Histoplasma capsulatum.

Authors:  B Wu-Hsieh; A Zlotnik; D H Howard
Journal:  Infect Immun       Date:  1984-01       Impact factor: 3.441

6.  Activation of neonatal and adult human macrophages by alpha, beta, and gamma interferons.

Authors:  C B Wilson; J Westall
Journal:  Infect Immun       Date:  1985-08       Impact factor: 3.441

7.  Dissection of macrophage tumoricidal and protozoacidal activities using T-cell hybridomas and recombinant lymphokines.

Authors:  W S Futch; L B Schook
Journal:  Infect Immun       Date:  1985-12       Impact factor: 3.441

8.  Macrophage activation: priming activity from a T-cell hybridoma is attributable to interferon-gamma.

Authors:  J L Pace; S W Russell; R D Schreiber; A Altman; D H Katz
Journal:  Proc Natl Acad Sci U S A       Date:  1983-06       Impact factor: 11.205

9.  Human lymphokine preparations which generate tumoricidal properties of human monocytes in vitro may be distinct from gamma interferon.

Authors:  E S Kleinerman; R H Wiltrout; R Zicht; I J Fidler
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

10.  Serum factor requirement for reactive oxygen intermediate release by rabbit alveolar macrophages.

Authors:  G F Gerberick; J B Willoughby; W F Willoughby
Journal:  J Exp Med       Date:  1985-02-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.